RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

Core Insights - RAPT Therapeutics, Inc. has appointed Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin, effective January 3, 2025 [1][2] - Lori Lyons-Williams brings over 20 years of experience in the pharmaceutical and biotech industries, currently serving as President and CEO of Abdera Therapeutics [2][3] - The company is focused on advancing its late-stage development and potential commercialization of therapies for inflammatory diseases, particularly RPT904 for food allergies and other allergic diseases [3] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology-based therapies for inflammatory and immunological diseases [1][3] - The company utilizes a proprietary discovery and development platform to create both biologics and selective small molecules aimed at normalizing immune drivers related to these conditions [3]